HL7 International
The standards body behind FHIR, the healthcare data interface now used to pull oncology records into trials, registries and AI tools, and home of the mCODE cancer data standard.
Founded in 1987, Health Level Seven International develops the messaging and data standards that let health IT systems exchange information, including HL7 v2, CDA and, since 2011, Fast Healthcare Interoperability Resources (FHIR), which US regulation now requires electronic health record vendors to support. For oncology, the minimal Common Oncology Data Elements (mCODE) implementation guide developed with ASCO's CodeX accelerator defines a core set of structured cancer data (diagnosis, staging, biomarkers, treatments, outcomes) so that records can feed registries, trial matching, real-world evidence and quality measurement without manual abstraction. HL7's work groups also cover genomics reporting and patient-reported outcomes.
- FHIR standard
- mCODE oncology data standard (with ASCO CodeX)
- Genomics reporting implementation guide
- HL7 v2 and CDA
Pages like this
not linked directly; found by shared links- IdeaSimulate eligibility against real-world data before every protocol is locked
Shares AI trial matching & clinical decision support, Trials enrol too few, too slowly, Weak real-world evidence and registries, Real-world evidence.
- IdeaNo mCODE, no payment: tie oncology reimbursement to a minimal structured record
Shares Weak real-world evidence and registries, Real-world evidence, Data silos.
- IdeaEvery payer covers routine care costs for trial participants, in every country
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaLay trial navigators funded per centre, evaluated in a randomised trial
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaStop excluding people with a prior cancer, controlled HIV, or treated hepatitis
Shares American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly, National Cancer Institute (NIH).
- IdeaPoint-of-care randomisation built into the oncology record
Shares Trials enrol too few, too slowly, Real-world evidence, Data silos.
- IdeaOpen, benchmarked algorithms for lines of therapy and progression from routine data
Shares Weak real-world evidence and registries, Real-world evidence, Data silos.
- IdeaJust-in-time site activation: open a site in two weeks when a patient appears
Shares AI trial matching & clinical decision support, American Society of Clinical Oncology (ASCO), Trials enrol too few, too slowly.